Jacob Johnson
Stock Analyst at Stephens & Co.
(2.88)
# 1,795
Out of 5,090 analysts
75
Total ratings
45.76%
Success rate
9.13%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $263.28 | -8.84% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.57 | -8.68% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.63 | -21.36% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $35.05 | +71.18% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $226.25 | +39.23% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $572.77 | +18.72% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $164.98 | +3.04% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.80 | +4.17% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.47 | +648.30% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $22.11 | +71.87% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.54 | +78.20% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.06 | +21.36% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $61.68 | +41.05% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $280.23 | +39.17% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $11.90 | +51.26% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.83 | +227.87% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $25.46 | +13.90% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $184.31 | +104.55% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $263.28
Upside: -8.84%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.57
Upside: -8.68%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.63
Upside: -21.36%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $35.05
Upside: +71.18%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $226.25
Upside: +39.23%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $572.77
Upside: +18.72%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $164.98
Upside: +3.04%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.80
Upside: +4.17%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.47
Upside: +648.30%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $22.11
Upside: +71.87%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.54
Upside: +78.20%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.06
Upside: +21.36%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $61.68
Upside: +41.05%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $280.23
Upside: +39.17%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $11.90
Upside: +51.26%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.83
Upside: +227.87%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $25.46
Upside: +13.90%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $184.31
Upside: +104.55%